Anaemia correction in predialysis elderly patients: Influence of the antihypertensive therapy on darbepoietin dose

International Urology and Nephrology

Volumn 39, Issue 2, 2007, Pages 685-689

  Neves, Pedro Leão ^a   Baptista, Alexandre ^a   Morgado, Elsa ^a   Iglesias, Alfonso ^a   Carrasqueira, Hermínio ^a   Faísca, Marília ^a   Soares, Carla ^a   Silva, Ana P ^a  

^a HOSPITAL DE FARO   (Portugal)

Author keywords

Antihypertensive drugs; Darbepoietin; Predialysis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

AGED; ANEMIA; ARTICLE; BIOCHEMISTRY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DEMOGRAPHY; DIALYSIS; DRUG DOSE COMPARISON; ERYTHROPOIESIS; FEMALE; GERIATRIC PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL ASSESSMENT;

AGED; AGED, 80 AND OVER; ANEMIA; ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE;

EID: 34447309296     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-006-9082-9     Document Type: Article

References (26)

1. Samiy AH (1984) Renal disease in the elderly. Med Clin North Am 67:463-480
2. Oreopoulos DG (1990) The aging kidney. Adv Perit Dial 6(Suppl):2-5
3. Raine AEG, Margreiter R, Brunner FP et al (1992) Report on management of renal failure in europe, XXII, 1991. Nephrol Dial Transplant 7(Suppl 2):7-35
4. Annual report (2002) ESRD clinical performance measures project. Am J Kidney Dis 39(Suppl 2):S4-S98
5. Eschbach JW, Adamson JW (1985) Anemia of end-stage renal disease (ESRD). Kidney Int 28:1-5
6. Erslev AJ, Besarab A (1997) Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 51:622-630
7. Revised European Best Practice Guidelines (2004) For the management of anaemia in patients with chronic renal failure. Section II: Targets for anaemia treatment. Nephrol Dial Transplant 19(Suppl 2):iI6-ii15
8. Acosta JH (1982) Hypertension in chronic renal disease. Kidney Int 22:702-712
9. Coca A (1998) Actual blood pressure control: Are we doing things right ? J Hypertens 16(Suppl 1):S45-S51
10. Juan PC, Weiliang C, Stavros L, Patrick V et al (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 366:2026-2033
11. Maschio G, Albert D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zuchelli P (1996) Angiotensin converting enzyme inhibition in progressive renal insufficiency study group. Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of renal insufficiency. N Engl J Med 334:939-945
12. Plum J, Blunten B, Nemeth R, et al (1998) Effect of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 9:2223-2234
13. Guidelines Committee (2003) 2003 European society of hypertension - European society of cardiology guidelines for the management of hypertension. J Hypertens 21:1011-1053
14. Chobanian A, Bakris GL, Black HR, et al (2003) The Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. J Am Med Assoc 289:2560-2572
15. Hirakata H, Onoyama K, Iseki K, Kumagai H, Fujimi S, Omae T (1984) Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol 4:355-360
16. Schwarzbeck A, Wittenmeier KW, Hallfritzsch U (1998) Anaemia in dialysis patients as a side-effect of sartanes. Lancet 352:286
17. Naito M, Kawashima A, Akiba T, Takanashi M, Nihei H (2003) Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Am J Neprol 23:287-293
18. Gault MH, Longerich LL, Harnett JD, Wesolowski C (1992) Predicting glomerular function from adjusted serum creatinine (editorial). Nephron 62:249
19. Kalantar-Zadeh K, Kleiner M, Dunne E, Lee GH, Luft FC (1999) A modified quantitative subjective global assessmet of nutrition for dialysis patients. Nephrol Dial Transplant 14:1732-1738
20. Kuriyama S, Tomonari H, Yoshida H et al (1997) Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176-185
21. Eggers PW (1990) Health care policies/economics of the geriatric renal population. Am J Kidney Dis 16:384-391
22. Friedman EA (2001) Must (should) all ESRD patients be treated? In: Levinsky NG (ed) Ethics and the kidney. Oxford University Press, Oxford, pp 85-98
23. Neves PL, Sousa A, Bernardo I et al (1994) Chronic haemodialysis for very old patients. Age Ageing 23:356-359
24. Woodhouse KW, Wynne H, Baille S et al (1988) Who are the frail elderly? Q J Med 255:505-506
25. Revised European Best Practice Guidelines (2004) For the management of anaemia in patients with chronic renal failure. Section IV: Failure to respond to treatment. Nephrol Dial Transplant 19(Suppl 2):iI32-ii36
26. Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16(Suppl 3):3-13